Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-04-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司第九届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the 10th meeting of the 9th Supervisory Board of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results, and references a related supervisory board opinion published elsewhere. The content focuses on governance matters, specifically the approval of a proposal regarding the use of idle raised funds and own funds for cash management. The document is short (675 characters) and serves as an official announcement of a board meeting resolution rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2024-04-10 Chinese
中信证券股份有限公司关于金陵药业股份有限公司使用闲置募集资金和自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Jinling Pharmaceutical Co., Ltd.'s use of idle raised funds and own funds for cash management. It references regulatory guidelines, approval from the board and supervisory committee, and includes specifics about the amount, purpose, risk control, and compliance with relevant securities regulations. The document is not a financial report itself but a regulatory compliance and verification statement related to the use of raised funds. It does not contain financial statements or earnings data. The length is 4176 characters, which is relatively short and the content is focused on verification and compliance rather than reporting financial results or management discussion. Therefore, it fits best under Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit other specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2024-04-10 Chinese
金陵药业股份有限公司关于向特定对象发行股票发行情况报告书披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (372 characters) regarding the disclosure of a report on a specific share issuance to designated investors. It states that the detailed report and related documents have been filed and are available on an external website. The text does not contain the actual report or detailed financial data but rather informs investors about the availability of the report. According to the 'Menu vs Meal' rule, such a brief notice that points to the report elsewhere is classified as a Report Publication Announcement (RPA).
2024-03-28 Chinese
金陵药业股份有限公司关于签订募集资金三方及四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of three-party and four-party supervision agreements related to the company's fundraising activities. It details the issuance of shares to specific investors, the amount of funds raised, the opening of special accounts for the funds, and the regulatory oversight agreements with banks and the sponsoring securities firm. The content focuses on the management and supervision of the raised capital rather than presenting financial statements or results. The document references regulatory approvals and agreements but does not contain financial performance data or audit results. It is a formal announcement about capital raising and related agreements, fitting the category of Capital/Financing Update (CAP). The document length is 4530 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or audit report.
2024-03-28 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司2023年度向特定对象发行A股股票发行过程和认购对象合规性的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a specific issuance of A shares by Jinling Pharmaceutical Co., Ltd. in 2023. It covers the compliance of the issuance process, approval and authorization by the board and shareholders, regulatory approvals, investor subscription details, pricing, allotment, and legal compliance of the issuance and investors. The document includes legal references, detailed procedural descriptions, and verification of compliance with securities laws and regulations. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital raising event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length and content confirm it is the actual legal opinion report, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2024-03-28 Chinese
金陵药业股份有限公司向特定对象发行A股股票募集资金验资报告
Audit Report / Information Classification · 95% confidence The document is titled as a "验资报告" which translates to "Capital Verification Report" or "Audit Report on Capital". It is issued by an accounting firm (天衡会计师事务所) and details the verification of newly issued shares and capital raised by the company 金陵药业股份有限公司. The report includes specifics on the number of shares issued, the amount of capital raised, and the related accounting verification procedures. It references regulatory approval from the China Securities Regulatory Commission and details the capital increase and share issuance. The document is not a full annual or interim financial report but a standalone audit verification report related to capital issuance. It is not a mere announcement or certification but contains substantive audit findings on the capital increase. Therefore, it fits the category of an Audit Report / Information (AR). Q1 2024
2024-03-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.